Zaire ebolavirus did not get a vaccine because anyone feared it in the abstract. It got one because, between 2014 and 2016, it killed more than 11,000 people across West Africa, reached the airports of the wealthy world, and arrived on American soil. Only then did the money move. Merck’s Ervebo, the rVSV shot that now rings each Zaire case with a vaccine Gavi itself calls “highly effective”, was built on a platform that had sat in laboratories for years. The science was ready long before the will was. Hold that sequence, because eastern Congo is living through it again: a virus virologists have studied since 2007, nineteen years with no licensed vaccine, and now a frantic scramble to test three experimental shots while the bodies are still being counted.

Bundibugyo virus is not new. It was first identified in 2007 in the Ugandan district that gave it its name, surfaced again in 2008, and returned to Isiro, in the Democratic Republic of the Congo, in 2012. It is a distinct species of orthoebolavirus with a historical case fatality rate between 25 and 50 percent. Researchers have known its genome, its glycoprotein, and its lethality for nineteen years. When this year’s outbreak began there was still no licensed vaccine against it and, in the language of the funders now rushing to fix that, none at an advanced stage of development. Nothing in trials, nothing awaiting approval, nothing in a pipeline at all.

Why the shot you have heard of cannot help here

It is worth understanding the mechanism, because it explains everything that follows. Ervebo uses a recombinant vesicular stomatitis virus, an animal virus harmless to people, as a delivery vehicle. That vehicle carries the surface glycoprotein of one species: Zaire ebolavirus. The immune system it builds is trained to recognize that one target. Bundibugyo’s glycoprotein is different enough that the licensed shot is not expected to protect against it, which is precisely why every agency is now building a separate one.

Here is the part that should end any argument about how prepared we were. The same platform was pointed at Bundibugyo years ago, and it worked: an rVSV vaccine displaying the Bundibugyo glycoprotein protected nonhuman primates against the virus in published animal studies. The engineering was not hypothetical. It was demonstrated, sitting on a shelf, waiting. What was missing was never the science. It was a market. Bundibugyo had never produced a body count large enough to interest a balance sheet, which is the quiet meaning of the phrase Gavi reaches for in its own materials: a “clear-cut case of market failure.”

The graveyard arrives

The reason finally arrived in Ituri Province. An initial sample came back negative for Zaire Ebola, the strain everyone was looking for, and had to travel to Kinshasa before Bundibugyo was confirmed in mid-May, with health workers already dying, four of them within a four-day span at a single referral hospital. The WHO declared a public health emergency of international concern on 17 May. By the time it published a detailed update on 19 June the count had reached 915 confirmed cases and 234 deaths, a case fatality rate near 26 percent that its own analysts warned was likely an undercount. Within days the Congolese health ministry was reporting more than 1,150 confirmed cases and over 300 deaths.

It runs higher because of where it is. This is a region carved up by armed groups, the ADF, CODECO, and Rwanda-backed M23, where humanitarian access is contested and surveillance has holes you could drive a convoy through. Researchers writing in Infection described the outbreak as a case study in surveillance vulnerability when Ebola meets conflict; a separate analysis in the International Journal of Infectious Diseases catalogued the delayed detection and preparedness gaps that let the virus run before the countermeasure machine even switched on. That is the population the system left without a vaccine for nineteen years, and the population least able to say no to whatever comes next.

The “race” is the receipt

What comes next is being narrated as triumph. BARDA stood up a program it calls BundiVx, with roughly $75 million to push candidates into human testing while the outbreak is still burning. CEPI fast-tracked three candidates at once: an rVSV approach from IAVI at up to $3.2 million, a ChAdOx1 viral-vector design from Oxford and the Serum Institute at up to $8.6 million, and an mRNA candidate from Moderna, the same platform and the same company at the center of the COVID vaccine push, funded at up to $50 million. The mRNA bid drew more than ten times what the proven rVSV approach got. CEPI separately put $1.9 million into Public Health Vaccines’ own rVSV Bundibugyo shot. The BMJ put it plainly: three vaccines, rushed into development.

Read it against the timeline and the triumph inverts. This is not preparedness. It is the autopsy of a market failure, performed in public, with the patient still in the room. Every dollar now moving at emergency speed could have moved in 2008, or 2012, or any of the calm years in between, when the same agencies and the same companies held the same platform and chose other priorities. A countermeasure program that activates only when the case counts and the cameras arrive is not a safety net. It is a reflex.

And these are experimental products. None has human efficacy data against Bundibugyo, because none existed to generate it until people started dying. Gavi concedes the obvious in its own write-up: no Bundibugyo-specific rVSV vaccine has been tested in people. The plan is to test them now, mid-outbreak, in a war zone, on the population with the fewest alternatives and the least power to refuse. An outbreak becomes a clinical-trial opportunity, and the people supplying the data are the ones who were left undefended for nineteen years.

Watch how the access question gets answered, because it already needs a watchdog. Public Citizen has had to write to BARDA noting that the U.S. government confirmed it is making the investigational antibody therapy available to Americans with high-risk exposures, while declining to say how many doses it holds or whether the affected countries will get any at all. The letter asks for the things that should be automatic: continued post-trial access for the communities supplying the trial data, affordable pricing, technology transfer so manufacturing is not hoarded, and protection against the trials being switched off the moment the outbreak fades from Western attention. That any of this has to be requested in writing tells you who the system serves when the doses are scarce.

None of that is an argument that the engineering is junk. The opposite. The platform is credible, an rVSV shot already protected primates against this exact virus, and that is what makes the nineteen-year delay damning rather than forgivable. But protecting a macaque is not protecting a mother in Ituri, plausible is not proven, and the unproven product and the desperate population are being introduced to each other in the worst conditions imaginable, because inattention left no other option.

We have seen this sequence before, with Zaire, and we will see it again with the next neglected species unless something other than the body count starts driving the budget. So watch the specifics. Watch which companies win the BundiVx awards and how fast a candidate reaches an arm. Watch the antibody readout for whether it holds up against Bundibugyo in people, not primates. And watch the one number BARDA has so far declined to give: how many doses reach Ituri, measured against how many sit in reserve for Washington. That ratio is the real test of preparedness. The vaccine race is just the part they are willing to film.

Sources

  1. WHO – Ebola disease caused by Bundibugyo virus, DRC and Uganda (Disease Outbreak News, 19 June 2026)
  2. WHO – Ebola disease caused by Bundibugyo virus, DRC (earlier Disease Outbreak News: timeline, health-worker deaths, no licensed vaccine)
  3. Gavi – From market failure to epidemic preparedness: the race for a Bundibugyo Ebola vaccine
  4. CEPI – fast-tracking three Bundibugyo ebolavirus vaccine candidates
  5. CEPI – awards Public Health Vaccines US$1.9m to accelerate a Bundibugyo ebolavirus vaccine
  6. TrialSite News – BARDA’s $75 million Bundibugyo (BundiVx) vaccine sprint
  7. Public Citizen – Letter to BARDA on Bundibugyo Ebola candidate therapeutics
  8. BMJ – Ebola: Three vaccines rushed into development for Bundibugyo outbreak
  9. International Journal of Infectious Diseases – delayed detection, preparedness gaps, and the vaccine race in the 2026 Bundibugyo outbreak
  10. Infection – When Ebola meets conflict: surveillance vulnerability in the Bundibugyo outbreak
  11. VSV-based vaccines protect nonhuman primates against Bundibugyo ebolavirus (PMC)